Could a Half-Dose strategy prevent bone loss after stopping osteoporosis meds?
NCT ID NCT07281586
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a gradual reduction of denosumab (Prolia) combined with zoledronic acid (Aclasta) can prevent bone loss after long-term osteoporosis treatment. 44 postmenopausal women and men over 50 who have taken denosumab for at least 3 years will be randomly assigned to either standard care or a de-escalation approach. The goal is to see if the new strategy better preserves bone density in the spine over two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
denosumab (half-dose) and zoledronic acid
What this could lead to
If it works, this could offer a safer way to stop long-term osteoporosis treatment without losing bone density.
What could go wrong
This is a small, early-phase trial with only 44 people, so results may not apply to everyone. The de-escalation strategy might not prevent bone loss as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Taiwan University Hospital Yunlin Branch
RECRUITINGDouliu, Taiwan, 640, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••